2018
Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Erradication
Vinaixa C, Belli L, Berenguer M, Cortesi P, Strazzabosco M, Faccheti R, Rockenschaub S, Martini S, Morelli C, Donato F, Volpes R, Pasulo L, Pageaux G, Coilly A, Perricone G, Mazzarelli C, Di Nicola S, Berlakovich G, Duvuox C. Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Erradication. Transplantation 2018, 102: s3. DOI: 10.1097/01.tp.0000542536.91165.49.Peer-Reviewed Original ResearchDirect acting antiviralsMedian Child-PughHepatocellular carcinomaChild-PughMedian followLiver transplantationMELD scoreClinical improvementSecond generation direct acting antiviralsClinical outcome 2 yearsDevelopment of HCCIntestine Transplant AssociationChronic HCV infectionLiver transplant candidatesLiver function testsStart of therapySignificant clinical improvementRisk of deathOutcomes 2 yearsDAA therapyEuropean LiverDecompensated cirrhosisHCV infectionAbdominal ultrasoundActing antiviralsThe optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
2016
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C, Association E. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal Of Hepatology 2016, 65: 524-531. PMID: 27212241, DOI: 10.1016/j.jhep.2016.05.010.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOral direct acting antiviralsClinical improvementChild-PughLiver transplantationActing antiviralsAdvanced liver diseaseChronic hepatitis CLiver transplant candidatesLow MELD scoresRemarkable clinical improvementHepatitis C virusDAA therapyDelta MELDDelta-albuminDAA combinationsHepatitis CMELD scoreViral eradicationCumulative incidenceLiver dysfunctionTransplant candidatesAntiviral therapyLiver diseaseLiver function
2010
Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria
De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, Pinelli D, Nani R, Valsecchi MG, Antolini L, Colledan M, Fagiuoli S, Strazzabosco M. Prediction of progression‐free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transplantation 2010, 16: 503-512. PMID: 20373461, DOI: 10.1002/lt.22039.Peer-Reviewed Original ResearchConceptsMilan criteriaProgression rateHepatocellular carcinomaRisk factorsObserved progression rateT2 patientsBarcelona Clinic Liver Cancer (BCLC) algorithmEnd-Stage Liver Disease exceptionOrgan allocationTumor persistence/recurrenceStage T2 patientsT2 hepatocellular carcinomaConsecutive HCC patientsProgression-free survivalChronic liver diseasePersistence/recurrenceDistinct natural historyTreatment of choiceBCLC guidelinesMELD scoreMELD exceptionsLocal therapyTransarterial chemoembolizationLiver diseaseTumor diameter